ArticleJournal of inflammation research2025
Elevated Serum HMGB1 Levels and Their Association with Stroke Risk of Paroxysmal Atrial Fibrillation.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to investigate the association between serum high mobility group box 1 (HMGB1) levels and stroke through the long-term follow-up of patients with paroxysmal atrial fibrillation (AF). Patients and Methods: The study was a prospective cohort study. A total of 304 patients with paroxysmal AF were enrolled, including 66 who underwent radiofrequency ablation (RFA). Serum HMGB1 levels were measured using an enzyme-linked immunosorbent assay. The primary endpoint was the first occurrence of a major adverse cerebrovascular event (MACE), defined as an acute ischemic stroke or all-cause mortality. Results: During the median follow-up of 81.5 months, 76 MACEs were recorded. Patients were categorized into MACE and no-MACE groups based on the occurrence of MACE. The MACE group showed significantly higher age, CHA Conclusion: Elevated serum HMGB1 level was identified as a significant predictor of stroke or mortality in patients with paroxysmal AF, and may enhance the predictive capacity of current risk stratification tools while supporting more personalized anticoagulation strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.